Dexmedetomidine ameliorates high‐fat diet‐induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice

Fatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no therapeutic drugs approved for this pathology. Insulin resistance (IR) is implicated both in pathogenesis of nonalcoholic fatty liver disease (NAFLD) and in disease progression from steatosis...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pharmacol Res Perspect
Asıl Yazarlar: Tao, Linfen, Guo, Xiaolong, Xu, Min, Wang, Yumeng, Xie, Wenhua, Chen, Hong, Ma, Mengyao, Li, Xi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7753983/
https://ncbi.nlm.nih.gov/pubmed/33474802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.700
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller